Related Party Transactions

12 Months Ended

Dec. 31, 2016

10.	Related Party Transactions

From July 2010 to November 2013, the Company manufactured and sold products to Allergan at Juniper’s cost plus 10%; the revenues generated from these sales were recorded within product revenues from related party. Pursuant to the Purchase and Collaboration Agreement dated July 2, 2010, Juniper received royalties equal to a minimum of 10% of annual net sales of CRINONE by Allergan for annual net sales up to $150 million, 15% for sales above $150 million but less than $250 million; and 20% for annual net sales of $250 million and over.

On March 7, 2014 the Company acquired all of its common stock beneficially owned by Allergan, which represented approximately 11.5% of the Company’s outstanding common stock. Immediately following the closing of the stock repurchase and as of December 31, 2014, Allergan did not own any of the Company’s outstanding common stock. Juniper purchased the 1.4 million shares held by Allergan at a price of $6.08 per share, which represented a 10.75% discount to the market closing price on March 6, 2014. The total purchase price was approximately $8.5 million.

The table below presents the related party transactions between the Company and Allergan for the year ended December 31, 2014 (in thousands):

	2014
Revenues:
Product revenues	$	167
Royalties		714
Other revenues		—
Total revenues		881
Cost of product revenues:
Cost of product revenues		—
Gross profit	$	881

As of December 31, 2016 and December 31, 2015, nothing was due from related party for these sales. There were no amounts due to Allergan as of December 31, 2016 and December 31, 2015.